About the Authors
- Rafael Dal-Ré
Affiliation Early Detection Research Program, Alzheimer's Disease, Pasqual Maragall Foundation, Barcelona, Spain
- David Moher
Affiliation Clinical Epidemiology Program, Ottawa Hospital Research Institute; Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada
- Christian Gluud
Affiliation Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
- Shaun Treweek
Affiliation Population Health Sciences, School of Medicine, University of Dundee and Tayside Clinical Trials Unit, Dundee, United Kingdom
- Jacques Demotes-Mainard
Affiliations INSERM, Paris, France, European Clinical Research Infrastructures Network (ECRIN), Paris, France
- Xavier Carné
Affiliation Clinical Pharmacology Service, Hospital Clinic, University of Barcelona, Barcelona, Spain
RDR reports being a GlaxoSmithKline employee (as Medical Director in Spain) until 2009 and owning stock in this firm. XC is the chairperson of the Spanish Commmittee of Drug Evaluation, an external advisory board to the Spanish Medicines Agency (AEMPS). DM is a member of the PLoS Medicine Editorial Board. The ideas and opinions expressed here are those of the authors and do not necessarily reflect those of the institutions or organizations they work for. All other authors reported having no competing interests.
Wrote the first draft of the manuscript: RDR. Contributed to the writing of the manuscript: RDR DM CG ST JDM XC. ICMJE criteria for authorship read and met: RDR DM CG ST JDM XC. Agree with manuscript results and conclusions: RDR DM CG ST JDM XC. Involved in the critical revision of the manuscript for important intellectual content: RDR DM CG ST JDM XC.